Former Taro Executive Faces US Antitrust Indictment

Ara Aprahamian Accused Of Price-Fixing And Allocating Customers

Former Taro executive Ara Aprahamian has been accused in the US of conspiracies covering generic price-fixing and allocation of customers, as well as for making false statements to investigating federal agents.

Department of Justice
The Department of Justice announced the indictment • Source: Shutterstock

Former Taro executive Ara Aprahamian has been accused in the US of conspiracies covering generic price-fixing and allocation of customers, as well as for making false statements to investigating federal agents, according to the US Department of Justice.

Aprahamian was vice-president of sales and marketing at Taro from March 2013 to August 2018.

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin